Argenx to Announce Q1 2025 Financial Results on May 8
International | Sector: Biotech & Pharma | Date: May 1, 2025
Argenx SE, a global immunology company, has scheduled the release of its first-quarter 2025 financial results and business update for Thursday, May 8, 2025. The company will host a conference call and audio webcast at 2:30 p.m. Central European Time (8:30 a.m. Eastern Time) to discuss the results and provide insights into its ongoing business strategies.
Key Details:
- Event: Q1 2025 Financial Results and Business Update
- Date: Thursday, May 8, 2025
- Time: 2:30 p.m. CET / 8:30 a.m. ET
- Access Code: 3810049
Dial-in Numbers:
- United States: 1 888 415 4250
- United Kingdom: 44 800 358 0970
- Belgium: 32 800 50 201
- France: 33 800 943355
- Netherlands: 31 20 795 1090
- Japan: 81 3 4578 9081
- Switzerland: 41 43 210 11 32
Participants are advised to dial in 15 minutes prior to the start of the call. A live webcast will be available on the Investors section of the Argenx website, and a replay will remain accessible for approximately one year following the presentation.
About Argenx: Argenx is dedicated to improving the lives of individuals suffering from severe autoimmune diseases. The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. Argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential across multiple serious autoimmune diseases, while also advancing several early-stage experimental medicines within its therapeutic franchises.
